1
|
Migliari S, Scarlattei M, Baldari G, Ruffini L. Scale down and optimized automated production of [68Ga]68Ga-DOTA-ECL1i PET tracer targeting CCR2 expression. EJNMMI Radiopharm Chem 2023; 8:3. [PMID: 36729317 PMCID: PMC9895323 DOI: 10.1186/s41181-023-00188-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 01/13/2023] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Recently it has been identified a short peptide that showed allosteric antagonism against C-C motif chemokine receptor 2 (CCR2) expressed on inflammatory monocyte and macrophages. A 7-D-amino acid peptidic CCR2 inhibitor called extracellular loop 1 inverso (ECL1i), d(LGTFLKC) has been identified and labeled to obtain a new probe for positron emission tomography in pulmonary fibrosis, heart injury, abdominal aortic aneurysm inflammation, atherosclerosis, head and neck cancer. Our goal was to develop, optimize and validate an automated synthesis method for [68Ga]68Ga-DOTA-ECL1i to make it available for a broader community. The synthesis of [68Ga]68Ga-DOTA-ECL1i was done using the Scintomics GRP® module with the already estabilished synthesis template for [68Ga]68Ga-DOTATOC/[68Ga]68Ga-PSMA. The radiopharmaceutical production was optimized scaling down the amount of DOTA-ECL1i (from 50 to 10 μg), evaluating synthesis efficiency and relevant quality control parameters in accordance with the European Pharmacopeia. RESULTS Best results were yielded with 20 μg DOTA-ECL1i and then the process validation was carried out by producing three different batches on three different days obtaining an optimal radiochemical yield (66.69%) as well as radiochemical purity (100%) and molar activity (45.41 GBq/µmol). CONCLUSIONS [68Ga]68Ga-DOTA-ECL1i was successfully synthesized and it is, thus, available for multi-dose application in clinical settings.
Collapse
Affiliation(s)
- Silvia Migliari
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Maura Scarlattei
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Giorgio Baldari
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| | - Livia Ruffini
- grid.411482.aNuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Via Gramsci 14, 43126 Parma, Italy
| |
Collapse
|
2
|
Alluri SR, Higashi Y, Kil KE. PET Imaging Radiotracers of Chemokine Receptors. Molecules 2021; 26:molecules26175174. [PMID: 34500609 PMCID: PMC8434599 DOI: 10.3390/molecules26175174] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 08/24/2021] [Accepted: 08/24/2021] [Indexed: 12/12/2022] Open
Abstract
Chemokines and chemokine receptors have been recognized as critical signal components that maintain the physiological functions of various cells, particularly the immune cells. The signals of chemokines/chemokine receptors guide various leukocytes to respond to inflammatory reactions and infectious agents. Many chemokine receptors play supportive roles in the differentiation, proliferation, angiogenesis, and metastasis of diverse tumor cells. In addition, the signaling functions of a few chemokine receptors are associated with cardiac, pulmonary, and brain disorders. Over the years, numerous promising molecules ranging from small molecules to short peptides and antibodies have been developed to study the role of chemokine receptors in healthy states and diseased states. These drug-like candidates are in turn exploited as radiolabeled probes for the imaging of chemokine receptors using noninvasive in vivo imaging, such as positron emission tomography (PET). Recent advances in the development of radiotracers for various chemokine receptors, particularly of CXCR4, CCR2, and CCR5, shed new light on chemokine-related cancer and cardiovascular research and the subsequent drug development. Here, we present the recent progress in PET radiotracer development for imaging of various chemokine receptors.
Collapse
Affiliation(s)
- Santosh R. Alluri
- University of Missouri Research Reactor, University of Missouri, Columbia, MO 65211, USA;
| | - Yusuke Higashi
- Department of Medicine, Tulane University, New Orleans, LA 70112, USA;
| | - Kun-Eek Kil
- University of Missouri Research Reactor, University of Missouri, Columbia, MO 65211, USA;
- Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO 65211, USA
- Correspondence: ; Tel.: +1-(573)-884-7885
| |
Collapse
|
3
|
Auvynet C, Baudesson de Chanville C, Hermand P, Dorgham K, Piesse C, Pouchy C, Carlier L, Poupel L, Barthélémy S, Felouzis V, Lacombe C, Sagan S, Chemtob S, Quiniou C, Salomon B, Deterre P, Sennlaub F, Combadière C. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration. FASEB J 2016; 30:2370-81. [PMID: 26979087 DOI: 10.1096/fj.201500116] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 02/25/2016] [Indexed: 11/11/2022]
Abstract
CC chemokine receptor type 2 (CCR2) is a key molecule in inflammatory diseases and is an obvious drug target for the treatment of inflammation. A number of nonpeptidic, competitive CCR2 antagonists have been developed, but none has yet been approved for clinical use. Our aim was to identify a short peptide that showed allosteric antagonism against human and mouse CCR2. On the basis of sequence analysis and 3-dimensional modeling, we identified an original 7-d-amino acid peptidic CCR2 inhibitor that we have called extracellular loop 1 inverso (ECL1i), d(LGTFLKC). In vitro, ECL1i selectively and potently inhibits CC chemokine ligand type 2 (CCL2)-triggered chemotaxis (IC50, 2 µM) but no other conventional CCL2-associated events. We used the classic competitive CCR2 antagonist, BMS22 {2-[(isopropylaminocarbonyl)amino]-N-[2-[[cis-2-[[4-(methylthio)benzoyl]amino]cyclohexyl]amino]-2-oxoethyl]-5-(trifluoromethyl)benzamide}, as positive control and inhibited CCL2-dependent chemotaxis with an IC50 of 18 nM. As negative control, we used a peptide with the same composition as ECL1i, but in a different sequence, d(FKLTLCG). In vivo, ECL1i (4 mg/kg) interfered with CCR2-positive cell recruitment and attenuated disease progression in experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. This study establishes ECL1i as the first allosteric inhibitor of CCR2 with functional selectivity. ECL1i is a promising new agent in therapeutic development, and it may, by its selective effect, increase our understanding of CCR2 signaling pathways and functions.-Auvynet, C., Baudesson de Chanville, C., Hermand, P., Dorgham, K., Piesse, C., Pouchy, C., Carlier, L., Poupel, L., Barthélémy, S., Felouzis, V., Lacombe, C., Sagan, S., Salomon, B., Deterre, P., Sennlaub, F., Combadière, C. ECL1i, d(LGTFLKC), a novel, small peptide that specifically inhibits CCL2-dependent migration.
Collapse
Affiliation(s)
- Constance Auvynet
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Camille Baudesson de Chanville
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Patricia Hermand
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Karim Dorgham
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Christophe Piesse
- Sorbonne Universités, UPMC/Univ Paris 06, Institut de Biologie Paris-Seine (IBPS) 3631, CNRS, Service de Synthése Peptidique, Paris, France
| | - Charlotte Pouchy
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Ludovic Carlier
- Sorbonne Universités, UPMC/Univ Paris 06, CNRS, UMR 7203, Laboratoire des Biomolécules, Paris, France
| | - Lucie Poupel
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Sandrine Barthélémy
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Virginie Felouzis
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Claire Lacombe
- Sorbonne Universités, UPMC/Univ Paris 06, CNRS, UMR 7203, Laboratoire des Biomolécules, Paris, France; Ecole Normale Supérieure-Université de Recherche Paris Sciences et Lettres, Département de Chimie, Paris, France; Faculté des Sciences et Technologie, Université Paris Est Créteil-Val de Marne, Créteil, France
| | - Sandrine Sagan
- Sorbonne Universités, UPMC/Univ Paris 06, CNRS, UMR 7203, Laboratoire des Biomolécules, Paris, France
| | | | | | - Benoit Salomon
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Philippe Deterre
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France
| | - Florian Sennlaub
- Sorbonne Universités, UPMC/ Univ Paris 06, UMRS 968, INSERM, U968, Institut de la Vision, Paris, France; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, INSERM-Direction des Hôpitaux et de l'Offre de Soins (DHOS), Centre d'Investigation Clinique 503, Paris, France
| | - Christophe Combadière
- *Sorbonne Universités, Université Pierre et Marie Curie (UPMC)/Univ Paris 06, Unité Mixte de Recherche Scientifique (UMRS) 1135, INSERM Unité 1135, Centre National de la Recherche Scientifique, Equipe de Recherche Labellisée (ERL) 8255, Centre d'Immunologie et des Maladies Infectieuses, Paris, France;
| |
Collapse
|
4
|
Brzoza Z, Grzeszczak W, Rogala B, Trautsolt W, Moczulski D. Possible contribution of chemokine receptor CCR2 and CCR5 polymorphisms in the pathogenesis of chronic spontaneous autoreactive urticaria. Allergol Immunopathol (Madr) 2014; 42:302-6. [PMID: 23727176 DOI: 10.1016/j.aller.2013.02.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2012] [Revised: 02/11/2013] [Accepted: 02/18/2013] [Indexed: 11/15/2022]
Abstract
BACKGROUND Autoimmune mechanisms play a role in the pathophysiology of chronic urticaria. As the genetic background of autoimmunity is well proven, the role of genetics in chronic urticaria is hypothesised. METHODS 153 unrelated chronic spontaneous urticaria patients with a positive result of autologous serum skin test were included into the study, as were 115 healthy volunteers as control group. In all subjects we analysed CCR2 G190A and CCR5 d32 polymorphisms. RESULTS We noticed higher prevalence of CCR2 A allele as well as lower frequency of CCR5 d32 in chronic urticaria group in comparison to control group, with borderline statistical significance. Additionally, we assumed haplotype Gd statistically significant negative chronic urticaria association with tendency to higher frequency of Aw haplotype in this group. CONCLUSIONS The results of our study imply the role of autoimmune components in chronic urticaria pathogenesis and present chronic urticaria as possibly genetically related disorder.
Collapse
Affiliation(s)
- Z Brzoza
- Chair and Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.
| | - W Grzeszczak
- Chair and Clinical Department of Internal Diseases, Diabetology and Nephrology, Medical University of Silesia, Katowice, Poland
| | - B Rogala
- Chair and Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland
| | - W Trautsolt
- Chair and Clinical Department of Internal Diseases, Diabetology and Nephrology, Medical University of Silesia, Katowice, Poland
| | - D Moczulski
- Chair and Clinical Department of Internal Diseases and Nephrodiabetology, Medical University of Łódź, Łódź, Poland
| |
Collapse
|
5
|
White GE, Iqbal AJ, Greaves DR. CC chemokine receptors and chronic inflammation--therapeutic opportunities and pharmacological challenges. Pharmacol Rev 2013; 65:47-89. [PMID: 23300131 DOI: 10.1124/pr.111.005074] [Citation(s) in RCA: 210] [Impact Index Per Article: 19.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Chemokines are a family of low molecular weight proteins with an essential role in leukocyte trafficking during both homeostasis and inflammation. The CC class of chemokines consists of at least 28 members (CCL1-28) that signal through 10 known chemokine receptors (CCR1-10). CC chemokine receptors are expressed predominantly by T cells and monocyte-macrophages, cell types associated predominantly with chronic inflammation occurring over weeks or years. Chronic inflammatory diseases including rheumatoid arthritis, atherosclerosis, and metabolic syndrome are characterized by continued leukocyte infiltration into the inflammatory site, driven in large part by excessive chemokine production. Over years or decades, persistent inflammation may lead to loss of tissue architecture and function, causing severe disability or, in the case of atherosclerosis, fatal outcomes such as myocardial infarction or stroke. Despite the existence of several clinical strategies for targeting chronic inflammation, these diseases remain significant causes of morbidity and mortality globally, with a concomitant economic impact. Thus, the development of novel therapeutic agents for the treatment of chronic inflammatory disease continues to be a priority. In this review we introduce CC chemokine receptors as critical mediators of chronic inflammatory responses and explore their potential role as pharmacological targets. We discuss functions of individual CC chemokine receptors based on in vitro pharmacological data as well as transgenic animal studies. Focusing on three key forms of chronic inflammation--rheumatoid arthritis, atherosclerosis, and metabolic syndrome--we describe the pathologic function of CC chemokine receptors and their possible relevance as therapeutic targets.
Collapse
Affiliation(s)
- Gemma E White
- Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom
| | | | | |
Collapse
|
6
|
Anastasopoulos E, Kakoulidou A, Coleman AL, Sinsheimer JS, Wilson MR, Yu F, Salonikiou A, Koskosas A, Pappas T, Founti P, Lambropoulos A, Topouzis F. Association of sequence variation in the CX3CR1 gene with geographic atrophy age-related macular degeneration in a Greek population. Curr Eye Res 2012; 37:1148-55. [PMID: 22816662 DOI: 10.3109/02713683.2012.705413] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PURPOSE To explore the association of two single nucleotide polymorphisms (SNPs) in the CX3CR1 gene with grades of age-related macular degeneration (AMD) in a population-based setting. METHODS The Thessaloniki Eye study is a cross-sectional population-based epidemiologic study of chronic eye diseases in Thessaloniki, Greece. A total of 371 subjects were included and classified according to their AMD status. Subjects with AMD Grades 0-1 (n = 188) were compared to those with AMD Grades 2-3 (n = 138), to those with AMD Grade 4 (geographic atrophy) (n = 20) and to those with AMD Grade 5 (neovascular AMD) (n = 25) with regard to the presence of CX3CR1 polymorphisms (V249I and T280M). Polychotomous logistic regression analysis adjusted for age, gender, and smoking was conducted and the log-additive allelic model was preferred. RESULTS Participants with AMD Grade 4 were approximately three times more likely to carry the VI249 and nine times more likely to carry the II249 alleles, compared to those with AMD Grades 0-1, whereas those with AMD Grades 2-3 or Grade 5 did not differ. The T280M polymorphism was not associated with either AMD Grades 2-3 or AMD Grades 4 or 5. CONCLUSION In this Greek population, after adjusting for known risk factors, increased risk of geographic atrophy (GA) AMD among the carriers of the V249I polymorphism in the CX3CR1 gene was found. Our study failed to reveal any association with the T280M polymorphism reported in previous studies. Additional studies in different ethnic populations using standardized methodology are needed in order to confirm this association.
Collapse
Affiliation(s)
- Eleftherios Anastasopoulos
- A' Department of Ophthalmology, School of Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Sabate JM, Ameziane N, Lamoril J, Jouet P, Farmachidi JP, Soulé JC, Harnois F, Sobhani I, Jian R, Deybach JC, de Prost D, Coffin B. The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behavior in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2008; 20:748-55. [PMID: 18617779 DOI: 10.1097/meg.0b013e3282f824c9] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
OBJECTIVES CX3CR1, the receptor of CX3CL1/fractalkine, is involved in regulation of inflammatory response and the CX3CR1-I249-M280 naturally occurring mutants are associated with altered binding to the ligand. Our aim was to evaluate the frequency of CX3CR1 V249I and T280M polymorphisms and NOD2/CARD15 mutations in Crohn's disease patients and to search for a relationship with phenotype. METHODS Clinical data were retrospectively collected. V249I and T280M polymorphisms of CX3CR1 gene and NOD2/CARD15 mutations (R702W, G908R, 3020InsC) were identified. RESULTS Two hundred and thirty-nine patients (140 females, 39.7+/-14.1 years) were included. About 37.4% were heterozygous and 8.8% were homozygous for the V249I CX3CR1 polymorphism, 18.1% were heterozygous and 1.3% homozygous for the T280M CX3CR1 polymorphism and 35.9% had at least one of the three mutations of NOD2/CARD15. The T280M CX3CR1 polymorphism was not associated with any phenotype. In univariate analysis, stenosis was significantly associated with both V249I CX3CR1 polymorphism and 3020InsC NOD2/CARD15 mutations. In smoker patients carrying the CX3CR1 allele I249, there was a significant increase in the frequency of fibrostenosing disease [P=0.005, odds ratio (OR): 3.25] whereas this relationship disappeared in the group of nonsmokers (P=0.72). In multivariate analysis, 3020InsC NOD2/CARD15 mutations and the V249I CX3CR1 polymorphism were independent risk factors for intestinal stenosis (P=0.046, OR: 1.8 and P=0.044, OR: 2.4, respectively). CONCLUSION In Crohn's disease, V249I CX3CR1 polymorphism is associated with intestinal strictures, particularly in smokers. This association is independent of CARD15 mutations.
Collapse
Affiliation(s)
- Jean-Marc Sabate
- Department of Gastroenterology and Hepatology, AP-HP, Louis Mourier Hospital, Colombes, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|